The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer.
 
Muralidhar Beeram
Honoraria - Genentech (Inst); Johnson & Johnson (Inst)
Consulting or Advisory Role - Bayer (I); Merck (I); Novartis (I); Seagen (I)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
Research Funding - Agios (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Phoenix Molecular Designs (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Genentech; Merck
 
Pavani Chalasani
Consulting or Advisory Role - Amgen; Asthenext; AstraZeneca; Bayer; Eisai; HERON; Lilly; NanoString Technologies; Puma Biotechnology
Research Funding - Pfizer
Patents, Royalties, Other Intellectual Property - Provisional patent submitted for using Syndros for management of pain from bone metastases (Inst)
 
Judy S. Wang
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - Acerta Pharma/AstraZeneca (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen Research & Development (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); QiLu Pharmaceutical (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Vedanta Biosciences (Inst); Vigeo Therapeutics (Inst); Xencor (Inst)
 
Lida A. Mina
No Relationships to Disclose
 
Rebecca Arielle Shatsky
Consulting or Advisory Role - SOTERIA Precision Medicine
Research Funding - Oncternal Therapeutics (Inst); Phoenix Molecular Designs (Inst)
 
Meghna S. Trivedi
Honoraria - Onclive
 
Robert Wesolowski
Consulting or Advisory Role - Roche
Speakers' Bureau - ONCOLIVE
Travel, Accommodations, Expenses - Roche
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Hyo S. Han
Consulting or Advisory Role - Pfizer
Speakers' Bureau - Lilly
Research Funding - Abbvie (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Department of Defense (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Horizon Oncology Research (Inst); Marker Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prescient Therapeutics (Inst); QuantumLeap Health (Inst); Seagen (Inst); Zymeworks (Inst)
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Genentech/Roche (I); Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - Abbvie (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Ionova (Inst); Klus Pharma (Inst); Lilly (Inst); Livzon (Inst); Merck (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Plexxikon (Inst); Sanofi (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Mary Rose Pambid
Employment - Phoenix Molecular Designs
 
Aarthi Jayanthan
Employment - Phoenix Molecular Designs
Patents, Royalties, Other Intellectual Property - Phoenix Molecular Designs
 
My-my Huynh
Employment - Phoenix Molecular Designs
Patents, Royalties, Other Intellectual Property - Phoenix Molecular Designs
 
Gerrit Los
Leadership - Phoenix Molecular Designs
Consulting or Advisory Role - Phoenix Molecular Designs
 
Sandra Elaine Dunn
Employment - Phoenix Molecular Designs
Leadership - Phoenix Molecular Designs
Stock and Other Ownership Interests - Phoenix Molecular Designs
Patents, Royalties, Other Intellectual Property - Phoenix Molecular Designs
 
Andrew Dorr
Leadership - Phoenix Molecular Designs
Consulting or Advisory Role - Phoenix Molecular Designs